May 12, 2022 / 05:40PM GMT
Franklin Jarman - Goldman Sachs Group, Inc., Research Division - VP & Senior Analyst
Okay. Well, thanks, everyone, for joining us. Our next panel is with Emergent BioSolutions. My name is Franklin Jarman. I'm a high yield health care analyst here and very excited to have Rich Lindahl, who is the EVP and CFO of the company; and Bob Burrows to his left, who is the Vice President of Investor Relations.
Questions and Answers:
Franklin Jarman - Goldman Sachs Group, Inc., Research Division - VP & Senior AnalystMaybe just to level set for everyone, I mean I think you guys have a fascinating business. And so I'd love to just maybe have you provide a little bit of an overview around the business model, some of your products and really how you think about the value proposition to the customer base overall.
Richard S. Lindahl - Emergent BioSolutions Inc. - Executive VP, CFO & Treasurer
Sure. Thank you, Frank, and thank you for having us here at the conference, and thank you all for taking the time to
Trustpilot
